drugset / Trial / NCT07428486
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
To find safe and effective doses of lisaftoclax and pelcitoclax in combination with FLAG chemotherapy in patients with relapsed/refractory T-ALL.
Timeline
- Start
- 2026-04-27
- Primary completion
- 2026-04-27
- Completion
- 2026-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | — | Oral |
| Subject | Pelcitoclax | Small molecule | — | Intravenous |
| Background | Cytarabine | Small molecule | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | G-CSF | Unknown | — | Other |